Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation

Nephrology

Volumn 11, Issue 5, 2006, Pages 449-454

  Miao, Lining ^a   Sun, Jing ^a   Yuan, Hang ^a   Jia, Ye ^a   Xu, Zhonggao ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Efficacy; Proliferation; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ORAL ANTIDIABETIC AGENT; PREDNISONE; SERUM ALBUMIN; TACROLIMUS;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OBESITY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; CELL DIVISION; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR MESANGIUM; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PREDNISONE; PROTEINURIA; SERUM ALBUMIN; TACROLIMUS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33749119351     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00667.x     Document Type: Article

References (20)

1. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-91.
2. Starzl TE, Todo S, Fung J et al. FK506 for liver, kidney, and pancreas transplantaton. Lancet 1989; 2: 1000-1004.
3. Laskow DA, Vincenti F, Neylan JF et al. An open label concentration-ranging trial of FK506 in primary kidney transplantation. A report of the United States Multicenter FK507 Kidney Transplantation Group. Transplantation 1996; 62: 900-905.
4. Woodle ES, Thistlethwaite JR, Gordon JH et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study group. Transplantation 1996; 62: 594-9.
5. Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or-dependent idiopatic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. 2002; 17: 655-62.
6. Mok CC, Tong KH, To CH et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney. Int. 2005; 68: 813-17.
7. Entani C, Izumino K, Iida H et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 1993; 64: 471-5.
8. Hara S, Fukatsu A, Suzuki N et al. The effects of a new immunosuppressive agent FK506 on the glomerular injury in rats with accelerated nephrotoxic serum sickness. Clin. Immunol. Immunopathol. 1990; 57: 351-62.
9. Hiromura K, Hayashi J, Tsukada Y et al. FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide. Kidney. Int. 1994; 45: 1572-9.
10. Okubo Y, Tsukada Y, Maezawa A et al. FK506 a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. Clin. Exp. Immunol. 1990; 82: 450-55.
11. Matsukawa W, Hara S, Yoshida F et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J. Lab. Clin. Med. 1992; 119: 116-23.
12. Kobayashi M, Muro K, Yoh K et al. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. Nephrol. Dial. Transplant. 1998; 13: 2501-8.
13. Nakahama H, Obata K, Matsuyama T et al. Effect of a novel immunosuppressant, FK506, on autoimmune glomerulonephritis in Brown Norway rats. Nephron 1999; 81: 215-20.
14. Ikezumi Y, Kanno K, Koike H et al. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int. 2002; 61: 1339-50.
15. Kramer BK, Schweda F. Differing proteinuria control with cyclosporin and tacrolimus. (Comment). Lancet 1997; 349: 953-4.
16. Wang SC, Zeevi A, Jordan ML et al. FK 506, rapamycin, and cyclosporine: Effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. Transplant. Proc. 1991; 23: 2920-22.
17. Wang T, Donahoe PK, Zervos AS. Specific interaction of Type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 1994; 265: 674-6.
18. Bishop DK, Li W. Cyclosporin A and FK 506 mediate differential effects on T cell activation in vivo. J. Immunol. 1992; 148: 1049-54.
19. Jain AB, Abu-Elmagd K, Abdallah H et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. Kidney Int. 2005; 68: 813-17.
20. Venkataramanan R, Jain A, Warty VS et al. Pharmacokinetics of FK506 in transplant patients. Transplant. Proc. 1991; 23: 2736-40.